Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Genitourinary 2Gastrointestinal 2Dermatologic 2Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 37Paclitaxel 18Cisplatin 18Carboplatin 14Nivolumab 13Hyperthermic Intraperitoneal Chemotherapy 13Docetaxel 11Cyclophosphamide 11Oxaliplatin 9Irinotecan 9Fluorouracil 9atezolizumab 8Trastuzumab 8Leucovorin 8Bevacizumab 8fludarabine 7Magnetic Resonance Spectroscopy 7Specimen Handling 6Ipilimumab 6Gemcitabine 6Mitomycin 5Cytoreduction Surgical Procedures 5Capecitabine 5durvalumab 4cemiplimab 4aldesleukin 4Taxes 4Psychiatric Rehabilitation 4Platinum 4Drug Therapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × utomilumab × Gynecologic × Clear all
NCT02315066 2022-04-21

Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566

Pfizer

Phase 1 Completed
174 enrolled 68 charts
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡